An overview of cyclophilins in human cancers

Journal of International Medical Research

Volumn 38, Issue 5, 2010, Pages 1561-1574

  Lee, J ^a   Kim, S S ^b  

^a Dongseo University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Cancer; Cyclophilins; Drug target; Peptidyl prolyl cis trans isomerase (PPIase)

Indexed keywords

CD147 ANTIGEN; CYCLOPHILIN; CYCLOPHILIN 20; CYCLOPHILIN 40; CYCLOPHILIN A; CYCLOPHILIN B; CYCLOPHILIN C; CYCLOPHILIN D; CYCLOPHILIN E; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHORIOCARCINOMA; COLORECTAL CANCER; ESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; GLIOMA; HUMAN; ISOMERIZATION; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MYELOMA; NEOPLASM; OXIDATIVE STRESS; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; UPREGULATION; UTERINE CERVIX CARCINOMA;

EID: 78449300481     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800501     Document Type: Review

References (110)

1. Handschumacher RE, Harding MW, Rice J, et al: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984; 226: 544-547.
2. Craescu CT, Rouvière N, Popescu A, et al: Three- dimensional structure of the immunophilin- like domain of FKBP59 in solution. Biochemistry 1996; 35: 11045-11052.
3. Fischer G, Tradler T, Zarnt T: The mode of action of peptidyl prolyl cis/trans isomerase in vivo: binding vs. catalysis. FEBS Lett 1998; 426: 17-20.
4. Schmid FX: Protein folding. Prolyl isomerases join the fold. Curr Biol 1995; 5: 993-994.
5. Schreiber SL: Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell 1992; 70: 365-368.
6. Göthel SF, Marahiel MA: Peptidyl-prolyl cis-trans isomerase, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999; 55: 423-436.
7. Hunter T: Prolyl isomerase and nuclear function. Cell 1998; 92: 141-143.
8. Rutherford SL, Zuker CS: Protein folding and the regulation of signaling pathways. Cell 1994; 79: 1129-1132.
9. Dolinski K, Scholz C, Muir RS, et al: Functions of FKBP12 and mitochondrial cyclophilin active site residues in vitro and in vivo in Saccharomyces cerevisiae. Mol Biol Cell 1997; 8: 2267-2280.
10. Liu J, Farmer JD Jr, Lane WS, et al: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815.
11. Ozaki K, Fujiwara T, Kawai A, et al: Cloning, expression and chromosomal mapping of a novel cyclophilin-related gene (PPIL1) from human fetal brain. Cytogenet Cell Genet 1996; 72: 242-245.
12. Galat A: Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr Top Med Chem 2003; 3: 1315-1347.
13. Waldmeier PC, Zimmermann K, Qian T, et al: Cyclophilin D as a drug target. Curr Med Chem 2003; 10: 1485-1506.
14. Arevalo-Rodriguez M, Wu X, Hanes SD, et al: Prolyl isomerases in yeast. Front Biosci 2004; 9: 2420-2446.
15. Anderson SK, Gallinger S, Roder J, et al: A cyclophilin-related protein involved in the function of natural killer cells. Proc Natl Acad Sci USA 1993; 90: 542-546.
16. Dornan J, Taylor P, Walkinshaw MD: Structures of immunophilins and their ligand complexes. Curr Top Med Chem 2003; 3: 1392-1409.
17. Andreeva L, Heads R, Green CJ: Cyclophilins and their possible role in the stress response. Int J Exp Pathol 1999; 80: 305-315.
18. Yurchenko V, Zybarth G, O'Connor M, et al: Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 1993; 277: 22959-22965.
19. Seko Y, Fujimura T, Taka H, et al: Hypoxia followed by reoxygenation induces secretion of cyclophilin A from cultured rat cardiac myocytes. Biochem Biophys Res Commun 2004; 317: 162-168.
20. Doyle V, Virji S, Crompton M: Evidence that cyclophilin-A protects cells against oxidative stress. Biochem J 1999; 341: 127-132.
21. Campa MJ, Wang MZ, Howard B, et al: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in non-small cell lung cancer. Cancer Res 2003; 63: 1652-1656.
22. Cecconi D, Astner H, Donadelli M, et al: Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2′-deoxycytidine. Electrophoresis 2003; 24: 4291-4303.
23. Lim SO, Park SJ, Kim W, et al: Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 2002; 291: 1031-1037.
24. Zheng J, Koblinski JE, Dutson LV, et al: Prolyl isomerase cyclophilin A regulation of Janus- activated kinase 2 and the progression of human breast cancer. Cancer Res 2008; 68: 7769-7778.
25. Hathout Y, Riordan K, Gehrmann M, et al: Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan. J Proteome Res 2002; 1: 435-442.
26. Han X, Yoon SH, Ding Y, et al: Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells. Oncol Rep 2010; 23: 1053-1062.
27. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res 2010; 29: 97.
28. Craig EA, Gambill BD, Nelson RJ: Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol Rev 1993; 57: 402-414.
29. Parsell DA, Lindquist S: The function of heat- shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu Rev Genet 1993; 27: 437-496.
30. Montague JW, Gaido ML, Frye C, et al: A calcium-dependent nuclease from apoptotic rat thymocytes is homologous with cyclophilin. Recombinant cyclophilins A, B, and C have nuclease activity. J Biol Chem 1994; 269: 18877-18880.
31. Lee J: Role of cyclophilin a during oncogenesis. Arch Pharm Res 2010; 33: 181-187.
32. Satoh K, Nigro P, Berk BC: Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal 2010; 12: 675-682.
33. Kim SH, Lessner SM, Sakurai Y, et al: Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol 2004; 164: 1567-1574.
34. Towers GJ, Hatziioannou T, Cowan S, et al: Cyclophilin A modulates the sensitivity of HIV- 1 to host restriction factors. Nat Med 2003; 9: 1138-1143.
35. Sherry B, Zybarth G, Alfano M, et al: Role of cyclophilin A in the uptake of HIV-1 by macrophages and T lymphocytes. Proc Natl Acad Sci USA 1998; 95: 1758-1763.
36. Hong F, Lee J, Song JW, et al: Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl- prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. FASEB J 2002; 16: 1633-1635.
37. Wiederrecht G, Lam E, Hung S, et al: The mechanism of action of FK-506 and cyclosporin A. Ann NY Acad Sci 1993; 696: 9-19.
38. 2+ homeostasis after ER stress. J Cell Sci 2008; 121: 3636-3648.
39. Zhang J, Herscovitz H: Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B. J Biol Chem 2003; 278: 7459-7468.
40. Marzo I, Brenner C, Zamzami N, et al: The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2- related proteins. J Exp Med 1998; 187: 1261-1271.
41. Lin DT, Lechleiter JD: Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization. J Biol Chem 2002; 277: 31134-31141.
42. Capano M, Virji S, Crompton M: Cyclophilin-A is involved in excitotoxin-induced caspase activation in rat neuronal B50 cells. Biochem J 2002; 363: 29-36.
43. Woodfield K, Rück A, Brdiczka D, et al: Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem J 1998; 336: 287-290.
44. Scorrano L, Nicolli A, Basso E, et al: Two modes of activation of the permeability transition pore: the role of mitochondrial cyclophilin. Mol Cell Biochem 1997; 174: 181-184.
45. 2+ and oxidant stress. Eur Biochem J 1996; 238: 166-172.
46. Mi H, Kops O, Zimmermann E, et al: A nuclear RNA-binding cyclophilin in human T cells. FEBS Lett 1996; 398: 201-205.
47. Wang Y, Han R, Zhang W, et al: Human CyP33 binds specifically to mRNA and binding stimulates PPIase activity of hCyP33. FEBS Lett 2008; 582: 835-839.
48. Zou J, Guo Y, Guettouche T, et al: Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998; 94: 471- 480.
49. Mark PJ, Ward BK, Kumar P, et al: Human cyclophilin 40 is a heat shock protein that exhibits altered intracellular localization following heat shock. Cell Stress Chaperones 2001; 6: 59-70.
50. Freeman BC, Toft DO, Morimoto RI: Molecular chaperone machines: chaperone activities of the cyclophilin Cyp-40 and the steroid aporeceptor-associated protein p23. Science 1996; 274: 1718-1720.
51. Johnson JL, Craig EA: Protein folding in vivo: unraveling complex pathways. Cell 1997; 90: 201-204.
52. Rinfret A, Collins C, Ménard R, et al: The N- terminal cyclophilin-homologous domain of a 150-kilodalton tumor recognition molecule exhibits both peptidylprolyl cis-trans-isomerase and chaperone activities. Biochemistry 1994; 33: 1668-1673.
53. - large granular lymphocytes. J Exp Med 1991; 174: 1527-1536.
54. Rassow J, Mohrs K, Koidl S, et al: Cyclophilin 20 is involved in mitochondrial protein folding in cooperation with molecular chaperones Hsp70 and Hsp60. Mol Cell Biol 1995; 15: 2654-2662.
55. Moparthi SB, Hammarström P, Carlsson U: A nonessential role for Arg 55 in cyclophilin18 for catalysis of proline isomerization during protein folding. Protein Sci 2009; 18: 475-479.
56. Lee S, Han X, Choi KJ, et al: A new method for purification of functional recombinant GST- cyclophilin A protein from E. coli. Indian J Biochem Biophys 2008; 45: 374-378.
57. Bosco DA, Eisenmesser EZ, Pochapsky S, et al: Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc Natl Acad Sci USA 2002; 99: 5247-5252.
58. Ishikawa Y, Wirz J, Vranka JA, et al: Biochemical characterization of the prolyl 3- hydroxylase 1.cartilage-associated protein. cyclophilin B complex. J Biol Chem 2009; 284: 17641-17647.
59. Konno M, Sano Y, Okudaira K, et al: Escherichia coli cyclophilin B binds a highly distorted form of trans-prolyl peptide isomer. Eur J Biochem 2004; 271: 3794-3803.
60. Friedman J, Trahey M, Weissman I: Cloning and characterization of cyclophilin C- associated protein: a candidate natural cellular ligand for cyclophilin C. Proc Natl Acad Sci USA 1993; 90: 6815-6819.
61. Basso E, Fante L, Fowlkes J, et al: Properties of the permeability transition pore in mitochondria devoid of cyclophilin D. J Biol Chem 2005; 280: 18558-18561.
62. Matas J, Young NT, Bourcier-Lucas C, et al: Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy. J Mol Cell Cardiol 2009; 46: 420-430.
63. Lu C, Armstrong JS: Role of calcium and cyclophilin D in the regulation of mitochondrial permeabilization induced by glutathione depletion. Biochem Biophys Res Commun 2007; 363: 572-577.
64. Ratajczak T, Carrello A: Cyclophilin 40 (CyP- 40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. J Biol Chem 1996; 271: 2961-2965.
65. Owens-Grillo JK, Hoffmann K, Hutchison KA, et al: The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor. J Biol Chem 1995; 270: 20479-20484.
66. Park S, Osmers U, Raman G, et al: The PHD3 domain of MLL acts as a CYP33-regulated switch between MLL-mediated activation and repression. Biochemistry 2010; 49: 6576-6586.
67. Lin CL, Leu S, Lu MC, et al: Over-expression of SR-cyclophilin, an interaction partner of nuclear pinin, releases SR family splicing factors from nuclear speckles. Biochem Biophys Res Commun 2004; 321: 638-647.
68. Choi K J, Piao YJ, Lim MJ, et al: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 2007; 67: 3654-3662.
69. Corton JC, Moreno ES, Merritt A, et al: Cloning genes responsive to a hepatocarcinogenic peroxisome proliferator chemical reveals novel targets of regulation. Cancer Lett 1998; 134: 61-71.
70. Howard BA, Zheng Z, Campa MJ, et al: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004; 46: 313-323.
71. Howard BA, Furumai R, Campa MJ, et al: Stable RNA interference-mediated suppression of cyclo- philin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res 2005; 65: 8853-8860.
72. Yang H, Chen J, Yang J, et al: Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun 2007; 361: 763-767.
73. Shen J, Person MD, Zhu J, et al: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004; 64: 9018-9026.
74. Li M, Wang H, Li F, et al: Effect of cyclophilin A on gene expression in human pancreatic cancer cells. Am J Surg 2005; 90: 739-745.
75. Li M, Zhai Q, Bharadwaj U, et al: Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006; 106: 2284-2294.
76. Mikuriya K, Kuramitsu Y, Ryozawa S, et al: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography- mass spectrometry/mass spectrometry. Int J Oncol 2007; 30: 849-855.
77. Melle C, Osterloh D, Ernst G, et al: Identification of proteins from colorectal cancer tissue by two- dimensional gel electrophoresis and SELDI mass spectrometry. Int J Mol Med 2005; 16: 11-17.
78. Lou J, Fatima N, Xiao Z, et al: Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev 2006; 15: 1598-1606.
79. Wong CS, Wong VW, Chan CM, et al: Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep 2008; 20: 89-98.
80. Chen J, He QY, Yuen AP, et al: Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics 2004; 4: 2465-2475.
81. Qi YJ, He QY, Ma YF, et al: Proteomic identification of malignant transformation- related proteins in esophageal squamous cell carcinoma. J Cell Biochem 2008; 104: 1625-1635.
82. Semba S, Huebner K: Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression. Mol Cancer Res 2006; 4: 529-538.
83. Lim SO, Park SJ, Kim W, et al: Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 2002; 291: 1031-1037.
84. Vorum H, Østergaard M, Hensechke P, et al: Proteomic analysis of hyperoxia-induced responses in the human choriocarcinoma cell line JEG-3. Proteomics 2004; 4: 861-867.
85. Al-Ghoul M, Brück TB, Lauer-Fields JL, et al: Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res 2008; 27: 4107-4118.
86. González-Santiago L, Alfonso P, Suárez Y, et al: Proteomic analysis of the resistance to aplidin in human cancer cells. J Proteome Res 2007; 6: 1286-1294.
87. Biswas C, Zhang Y, DeCastro R, et al: The human tumor cell derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-439.
88. Yurchenko V, Pushkarsky T, Li JH, et al: Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain. J Biol Chem 2005; 280: 17013-17019.
89. Boulos S, Meloni BP, Arthur PG, et al: Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis 2006; 25: 54-64.
90. Clarke SJ, McStay GP, Halestrap AP: Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 2002; 277: 34793-34799.
91. Ravi R, Mookerjee B, Bhujwalla ZM, et al: Regulation of tumor angiogenesis by p53- induced degradation of hypoxia-inducible factor 1α. Genes Dev 2000; 14: 34-44.
92. Greijer AE, van der Wall E: The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004; 57: 1009-1014.
93. Zhou J, Hara K, Inoue M, et al: Regulation of hypoxia-inducible factor 1 by glucose availability under hypoxic conditions. Kobe J Med Sci 2008; 53: 283-296.
94. Gu S, Liu Z, Pan S, et al: Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging. Mol Cell Proteomics 2004; 3: 998-1008.
95. Yu X, Harris SL, Levine AJ: The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006; 66: 4795-4801.
96. Gomi S, Nakao M, Niiya F, et al: A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999; 163: 4994-5004.
97. Mantovani F, Tocco F, Girardini J, et al: The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol 2007; 14: 912-920.
98. Allain F, Vanpouille C, Carpentier M, et al: Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin- mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci USA 2002; 99: 2714-2719.
99. Fang F, Flegler AJ, Du P, et al: Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer. Am J Pathol 2009; 174: 297-308.
100. Ward BK, Mark PJ, Ingram DM, et al: Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast Cancer Res Treat 1999; 58: 267-280.
101. Mark PJ, Ward BK, Kumar P, et al: Human cyclophilin 40 is a heat shock protein that exhibits altered intracellular localization following heat shock. Cell Stress Chaperones 2001; 6: 59-70.
102. Ward BK, Kumar P, Turbett GR, et al: Allelic loss of cyclophilin 40, an estrogen receptor-associatedimmunophilin, in breast carcinomas. J Cancer Res Clin Oncol 2001; 127: 109-115.
103. Barth S, Nesper J, Hasgall PA, et al: The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 2007; 27: 3758-3768.
104. Bauer K, Kretzschmar AK, Cvijic H, et al: Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene 2009; 28: 2784-2795.
105. Schubert A, Grimm S: Cyclophilin D. A component of the permeability transition- pore, is an apoptosis repressor. Cancer Res 2004; 64: 85-93.
106. Eliseev RA, Malecki J, Lester T, et al: Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect. J Biol Chem 2009, 284: 9692-9699.
107. Machida K, Ohta Y, Osada H: Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J Biol Chem 2006; 281: 14314-14320.
108. Miller RT, Anderson SP, Corton JC, et al: Apoptosis, mitosis and cyclophilin-40 expression in regressing peroxisome proliferator-inducedadenomas. Carcinogenesis 2000; 21: 647-652.
109. Mi Z, Oliver T, Guo H, et al: Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res 2007; 67: 4088-4097.
110. Chen G, Izzo J, Demizu Y, et al: Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. Antioxid Redox Signal 2009; 11: 1083-1095.